122 related articles for article (PubMed ID: 9930583)
21. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
22. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
[TBL] [Abstract][Full Text] [Related]
23. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
[TBL] [Abstract][Full Text] [Related]
24. Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs.
Baldissera FG; Holst JJ
Diabetologia; 1986 Jul; 29(7):462-7. PubMed ID: 3743926
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
Gutniak MK; Linde B; Holst JJ; Efendić S
Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
[TBL] [Abstract][Full Text] [Related]
26. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
Vilsbøll T; Agersø H; Krarup T; Holst JJ
J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
[TBL] [Abstract][Full Text] [Related]
27. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
Mizuno A; Kuwajima M; Ishida K; Noma Y; Murakami T; Tateishi K; Sato I; Shima K
Metabolism; 1997 Jul; 46(7):745-9. PubMed ID: 9225826
[TBL] [Abstract][Full Text] [Related]
28. Enteroglucagon.
Holst JJ
Annu Rev Physiol; 1997; 59():257-71. PubMed ID: 9074764
[TBL] [Abstract][Full Text] [Related]
29. Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat.
Sasaki M; Fitzgerald AJ; Mandir N; Sasaki K; Wright NA; Goodlad RA
Aliment Pharmacol Ther; 2001 Oct; 15(10):1681-6. PubMed ID: 11564010
[TBL] [Abstract][Full Text] [Related]
30. On the role of the gut in diabetic hyperglucagonaemia.
Lund A
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
[TBL] [Abstract][Full Text] [Related]
31. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
32. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats.
Fischer KD; Dhanvantari S; Drucker DJ; Brubaker PL
Am J Physiol; 1997 Oct; 273(4):E815-20. PubMed ID: 9357813
[TBL] [Abstract][Full Text] [Related]
33. The amino acid sequence of porcine glicentin.
Thim L; Moody AJ
Peptides; 1981; 2 Suppl 2():37-9. PubMed ID: 7045833
[TBL] [Abstract][Full Text] [Related]
34. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
35. Glucagon and its family revisited.
Lefèbvre PJ
Diabetes Care; 1995 May; 18(5):715-30. PubMed ID: 8586014
[No Abstract] [Full Text] [Related]
36. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals.
Messenger B; Clifford MN; Morgan LM
J Endocrinol; 2003 Jun; 177(3):407-12. PubMed ID: 12773121
[TBL] [Abstract][Full Text] [Related]
37. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes.
O'Donovan DG; Doran S; Feinle-Bisset C; Jones KL; Meyer JH; Wishart JM; Morris HA; Horowitz M
J Clin Endocrinol Metab; 2004 Jul; 89(7):3431-5. PubMed ID: 15240627
[TBL] [Abstract][Full Text] [Related]
38. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
Vahl TP; Paty BW; Fuller BD; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2003 Apr; 88(4):1772-9. PubMed ID: 12679472
[TBL] [Abstract][Full Text] [Related]
39. The peculiar processing of glucagon and glucagon-related peptides in patients after pancreatectomy.
Tanjoh K; Tomita R; Hayashi N
Hepatogastroenterology; 2002; 49(45):825-32. PubMed ID: 12064000
[TBL] [Abstract][Full Text] [Related]
40. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Orskov C; Jeppesen J; Madsbad S; Holst JJ
J Clin Invest; 1991 Feb; 87(2):415-23. PubMed ID: 1991827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
